



*Facility ID:	Event #:				
*Resident ID:					
Medicare number (or comparable railroad insurance nu	mber):				
*Resident Name: First: Middle:	Last:				
*Gender: F M Other	*Date of Birth:/				
*Ethnicity (specify): □ Hispanic or Latino	*Race (specify): □ American Indian/Alaska Native				
□ Not Hispanic or Latino	☐ Asian ☐ Black or African American ☐ Native				
□ Declined to respond □ Unknown	Hawaiian/Other Pacific Islander □ White				
•	□ Declined to respond □ Unknown				
*Veteran Resident Type: Veteran Veteran Spouse	Gold Star Parent Other (Specify)				
Event Details					
*Event Type: COVID-19	*Date of Current Admission to Facility:/_/				
*Date of Event://					
Resident COVID-19 Event Form					
*TEST TYPE: The resident was determined to have a newly positive SARS-CoV-2 viral test result using which of the following testing options (select only one):					
Positive SARS-CoV-2 antigen test only [no other testing performed]					
Positive SARS-CoV-2 NAAT (PCR) only [no other testing performed]					
*Positive SARS-CoV-2 antigen test and negative SARS-CoV-2 NAAT (PCR)					
*Any other combination of SARS-CoV-2 NAAT (PCR) and/or antigen test(s) with at least one positive test					
± Only select if the two tests were performed within 2 calendar days from initial test (test date is calendar day one). Otherwise, select the first test performed only.					
*RE-INFECTIONS: Respond to questions based on the current COVID-19 event (SARS-COV-2 infection):					
*Is the resident considered to be re-infected with SARS-CoV-2? \square Yes \square No					
**If applicable, was the resident symptomatic at the time of re-i	**If applicable, was the resident symptomatic at the time of re-infection? \Box Yes \Box No				





	STATUS: Indic	ate the vaccination st	atus of the resident on	the event date or date of	specimen
collection.					
Has the resident	received any C	OVID-19 vaccine? \Box	Yes □ No		
Has the resident	received an add	ditional or booster dos	se of vaccine? \square Yes	□ No	
Initial Vaccinati	on: Select all va	accine doses received	l, vaccination date, and	d vaccine manufacturer.	
* Dose 1 **Vaco	cination Date: <[Orop down menu>	** Manufacturer: <dr< td=""><td>•</td><td></td></dr<>	•	
	MM/DD/YYYY Unknown		JANSSEN – Janssen C	Tech COVID-19 vaccine	
*Dose 2 **Vacc	ination Date: <[Orop down menu>	** Manufacturer: <dro< td=""><td>o down menu></td><td></td></dro<>	o down menu>	
Additional or B	ooster Doses:	ndicate the date and	manufacturer for the a	additional or booster doses	s of vaccine.
**Additional or	Booster Dose	**Vaccination Date:	<drop down="" menu=""></drop>	** Manufacturer: <drop< td=""><td>down menu></td></drop<>	down menu>
**Additional or	Booster Dose	**Vaccination Date:	<drop down="" menu=""></drop>	** Manufacturer: <drop< td=""><td>down menu></td></drop<>	down menu>





*COVID-19 THERAPY: Indicate if the resident received on event (SARS COV-2 infection):	e of the following therapeutic options for the current COVID-19			
□ Did not receive				
□ Casirivimab plus Imdevimab (Regeneron)				
Received therapy from stock stored at this facility? \square Y	es □No			
□ Bamlanivimab plus etesevimab (Lilly)				
Received therapy from stock stored at this facility? \square Yes \square No				
□ Sotrovimab (GlaxoSmithKline)				
Received therapy from stock stored at this facility? □ Yes □ No				
*HOSPITALIZATION: Has the resident been admitted to a	*COVID-19 DEATH: Did the resident die from COVID-19 or related			
hospital or transferred to an acute care facility for this	complications?			
COVID-19 event?	□ Yes □ No			
□ Yes □ No	**Date of death/_/			
**Date of hospitalization/_ /				
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).				
CDC estimates the average public reporting burden for this collection of information as 40 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-1306). CDC 57.159 (Front) October 2021 V12				